Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry Eye Symptom Relief Assessed During Exposure to a Controlled Adverse Environment (CAE®) Following a 45 Day Period With Application of TrueTear™
Phase: NA
Conditions: Dry Eye, Dry Eye Syndromes
Sponsor: Oculeve, Inc.

NCT03097614  
 
 
Study ID: OCUN‐029 
 
 
Title: Prospective, Single‐Arm Clinical Trial to Evaluate Acute Dry Eye Symptom Relief Assessed During 
Exposure to a Controlled Adverse Environment (CAE®) Following a 45 Day Period with Application of 
TrueTear™ 
 
 
Protocol Date: March 10, 2017 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 1 of 50 
March 10, 2017   
 
Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry Eye Symptom Relief 
Assessed During Exposure to a Controlled Adverse Environment (CAE®) Following a 45 
Day Period with Application of TrueTear™ 
Protocol Number: 
OCUN-029 
Original Protocol:  
March 10, 2017 
Device Name: 
TrueTear™ 
Sponsor: 
Allergan, Inc. 
 
Contract Research 
Organization: 
 
 
 
 
 
 
Confidentiality Statement 
The following contains confidential, proprietary information which is the property of Allergan. 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 2 of 50 
March 10, 2017   
MEDICAL MONITOR 
 
  
 
SPONSOR PERSONNEL 
Executive Director, Clinical Trial Management: 
 
 
 
Executive Director, Clinical Development, Ophthalmology: 
 
 
 
  
 
 
 
 
 
 PERSONNEL 
Department Vice President: 
 
 
Department Senior Manager: 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 3 of 50 
March 10, 2017   
Clinical Project Management: 
 
 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 4 of 50 
March 10, 2017   
SYNOPSIS 
Protocol Title: 
Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry 
Eye Symptom Relief Assessed During Exposure to a 
Controlled Adverse Environment (CAE®) Following a 45 
Day Period with Application of TrueTear™ 
Protocol Number: 
OCUN-029 
Study Device(s): 
TrueTear™ 
Study Objective: 
The objective of this study is to characterize acute dry eye 
symptom relief assessed during exposure to a Controlled 
Adverse Environment (CAE) following use of TrueTear for 
45 days. 
Overall Study Design 
Structure: 
Prospective, single-arm, open-label study 
Duration: 
Approximate 21 day screening period and 45 day daily 
application period 
Device Regimen: 
Daily use of TrueTear per Instructions For Use (IFU) with in-
office tear production assessment at Day 7 and CAE 
assessments taking place on Days 0 and 45. 
Summary of Visit Schedule: 
Up to four visits over the course of approximately 66 days 
Visit 1 (Day -21 ± 20) - 
Screening Visit 
Visit 2 (Day 0) - 
Day 0 CAE Visit 
Visit 3 (Day 7 ± 2) - 
Tear Production Assessment 
Visit  
Visit 4 (Day 45 ± 7) - 
Day 45 CAE Visit 
Study Population Characteristics 
Number of Participants: 
Approximately 45 participants are required to receive the 
device application in the CAE on Day 45. Approximately 60 
participants may be enrolled at up to two sites to meet this 
goal. 
Condition/Disease: 
Dry Eye Disease 
Evaluation Criteria 
Effectiveness Measures:  
Primary Effectiveness Measure: 
The primary effectiveness measure will be Eye Dryness Score 
(EDS) using a visual analog scale (VAS) as assessed in the 
CAE at Day 45. 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 5 of 50 
March 10, 2017   
 
 
 
 
 
 
 
 
 
 
 
 
 
Safety Measures: 
 
   
 
  
 
   
Other Measures: 
• 
 
 
  
 
 
General Statistical Methods and Types of Analyses 
Sample Size 
Approximately 45 participants are required to receive the device application in the CAE on Day 
45. Approximately 125 participants may be screened and approximately 60 participants may be 
enrolled to meet this goal.  
Primary Effectiveness Analysis  
The primary effectiveness analysis will be acute symptom relief at Day 45 defined as the 
difference in the pre-application and post-application values, assessed using the EDS in the CAE. 
The test will be one-sided and evaluated at an α of 0.025 in the Full Analysis Set (FAS) 
population. 
Exploratory Effectiveness Analyses 
 
 
 
 
 
  
 
 
Safety Analyses 
. 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 6 of 50 
March 10, 2017   
TABLE OF CONTENTS 
SYNOPSIS .................................................................................................................................4 
TABLE OF CONTENTS ...........................................................................................................6 
TABLE OF FIGURES ...............................................................................................................8 
LIST OF ABBREVIATIONS ....................................................................................................9 
1.0 INTRODUCTION ...........................................................................................................10 
1.1 
Background ............................................................................................................10 
1.2 
Current Treatment Options for Dry Eye Disease ...................................................10 
1.3 
Rationale ................................................................................................................11 
1.4 
Controlled Adverse Environment Model ...............................................................12 
1.5 
Proposed Indication ...............................................................................................12 
2.0 STUDY OBJECTIVES ....................................................................................................12 
3.0 CLINICAL HYPOTHESES ............................................................................................12 
4.0 OVERALL STUDY DESIGN .........................................................................................12 
5.0 STUDY POPULATION ..................................................................................................13 
5.1 
Number of Participants ..........................................................................................13 
5.2 
Study Population Characteristics ...........................................................................13 
5.3 
Inclusion Criteria ...................................................................................................14 
5.4 
Exclusion Criteria ..................................................................................................14 
5.5 
Inclusion/Exclusion Exceptions .............................................................................15 
5.6 
Discontinuation Criteria (if applicable) .................................................................15 
6.0 STUDY PARAMETERS .................................................................................................16 
6.1 
Effectiveness Measures ..........................................................................................16 
 
Primary Effectiveness Measure ...................................................................16 
6.1.1
 
 
 
 
 
 
7.0 DEVICE DESCRIPTION ................................................................................................17 
 
Base Unit ......................................................................................................19 
7.1.1
 
Disposable Tip .............................................................................................19 
7.1.2
 
Cover ............................................................................................................19 
7.1.3
 
Charger .........................................................................................................19 
7.1.4
7.2 
Device Accountability ...........................................................................................19 
7.3 
Other Study Supplies .............................................................................................19 
8.0 STUDY METHODS AND PROCEDURES ...................................................................20 
8.1 
Participant Entry Procedures..................................................................................20 
 
Overview ......................................................................................................20 
8.1.1
 
Informed Consent.........................................................................................20 
8.1.2

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 7 of 50 
March 10, 2017   
 
Washout Intervals and Prohibited Treatments .............................................20 
8.1.3
 
Procedures for Final Study Entry .................................................................20 
8.1.4
 
Methods for Assignment of Participant Number .........................................20 
8.1.5
8.2 
Participant Training, Device Dispensing, and Home Use .....................................21 
8.3 
Concurrent Therapies .............................................................................................22 
8.4 
Examination Procedures ........................................................................................22 
 
Procedures to be Performed at the Screening Visit (Visit 1; Day -21 ± 20) 22 
8.4.1
 
Procedures to be Performed on the Day 0 CAE Visit (Visit 2; Day 0)) ......23 
8.4.2
 
Procedures to be Performed on Tear Production Assessment Visit (Visit 3; 
8.4.3
Day 7 ± 2) ....................................................................................................24 
 
Procedures to be Performed on Day 45 CAE Visit (Visit 4; Day 45 ± 7) ...24 
8.4.4
 
Early Termination/Discontinuation .............................................................25 
8.4.1
8.5 
Schedule of Visits ..................................................................................................25 
 
Scheduled Visits...........................................................................................25 
8.5.1
 
Unscheduled Visits ......................................................................................26 
8.5.2
8.6 
Completed Participants ..........................................................................................26 
8.7 
Study Termination .................................................................................................26 
8.8 
Study Duration .......................................................................................................26 
8.9 
Monitoring and Quality Assurance ........................................................................26 
 
Study Monitoring .........................................................................................26 
8.9.1
 
Recording of Data ........................................................................................27 
8.9.1
9.0 ADVERSE EVENTS .......................................................................................................27 
9.1 
Adverse Event Recording ......................................................................................27 
9.2 
Adverse Event Evaluation......................................................................................27 
9.3 
Relationship of the AE to the investigational device .............................................28 
9.4 
Serious and Unanticipated Adverse Device Effects ..............................................28 
9.5 
Adverse Event Reporting .......................................................................................29 
9.6 
Anticipated Adverse Events ...................................................................................30 
10.0 PREGNANCY .................................................................................................................30 
11.0 STATISTICAL HYPOTHESIS AND METHODS OF ANALYSES .............................31 
11.1 
Power Calculation and Determination of Sample Size ..........................................31 
11.2 
Statistical Hypotheses and Level of Significance ..................................................31 
11.3 
Randomization .......................................................................................................32 
11.4 
Evaluability of Data ...............................................................................................32 
11.5 
General Statistical Considerations .........................................................................32 
11.6 
Participant Accountability and Missing Data ........................................................32 
11.7 
Participant Demographic and Baseline Characteristics .........................................32 
11.8 
Effectiveness Analyses ..........................................................................................32 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 8 of 50 
March 10, 2017   
11.9 
Safety Analyses ......................................................................................................33 
12.0 FINAL CLINICAL STUDY REPORT ...........................................................................33 
13.0 COMPLIANCE WITH GOOD CLINICAL PRACTICES, ETHICAL 
CONSIDERATIONS, AND ADMINISTRATIVE ISSUES ...........................................33 
13.1 
Protection of Human Participants ..........................................................................33 
 Participant Informed Consent ................................................................................33 
13.1.1
 Institutional Review Board (IRB) Approval ..........................................................34 
13.1.2
 Ethical Conduct of the Study .................................................................................34 
13.1.3
 Participant Confidentiality .....................................................................................34 
13.1.4
13.2 
Documentation .......................................................................................................34 
 
Retention of Documentation ........................................................................34 
13.2.1
13.3 
Regulatory Status ...................................................................................................35 
13.4 
Labeling, Packaging, Storage, Accountability, and Return or Disposal of Study 
Device ....................................................................................................................35 
13.5 
Recording of Data on Source Documents and Case Report Forms (CRFs) ..........35 
13.6 
Amendments to the Protocol ..................................................................................35 
13.7 
Publications ............................................................................................................35 
14.0 REFERENCES ................................................................................................................36 
15.0 APPENDICES .................................................................................................................38 
15.1 
Appendix 1: Schedule of Visits and Measurements ..............................................39 
15.2 
Appendix 2: Examination Procedures, Tests, Equipment, and Techniques ..........40 
 
Visual Acuity Procedures ............................................................................40 
15.2.1
 
Slit Lamp Biomicroscopy ............................................................................41 
15.2.2
 Corneal Fluorescein Staining .......................................................................42 
15.2.2.1
 
Intranasal Examination ................................................................................43 
15.2.3
 
Basal Schirmer Test with Topical Anesthesia .............................................43 
15.2.4
 Dry Eye Questionnaires .........................................................................................45 
15.2.5
15.3 
Appendix 3: Sponsor and 
 Approvals ..............................................................49 
15.4 
Appendix 4: Investigator’s Signature ....................................................................50 
TABLE OF FIGURES 
Figure 1  
The TrueTear system components .................................................................... 18 
Figure 2  
Use of the TrueTear .......................................................................................... 22 
Figure 3  
Target area of cotton swab nasal stimulation .................................................... 44 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 9 of 50 
March 10, 2017   
LIST OF ABBREVIATIONS 
AE 
Adverse event 
ADE 
Adverse device effect 
CAE® 
Controlled adverse environment 
CDVA 
Corrected distance visual acuity 
CFR 
Code of Federal Regulations 
CI 
Confidence interval 
CRF 
Case report form 
DED 
Dry eye disease 
DEWS 
Dry eye workshop 
DHHS 
Department of Health and Human Services 
EDS 
Eye Dryness Score 
EMS 
Electro-neuromuscular stimulation 
ETDRS 
Early Treatment Diabetic Retinopathy Study 
FDA 
Food and Drug Administration 
FAS 
Full Analysis Set 
GCP 
Good clinical practice 
HIPAA 
Health Information Portability and Accountability Act 
ICF 
Informed consent form 
ICH 
International Conference on Harmonisation 
IFU 
Instructions for use 
IRB 
Institutional/independent review board 
LASEK 
Laser assisted sub-epithelial keratectomy 
LASIK 
Laser-assisted in situ keratomileusis 
LED 
Light-emitting diode 
LFU 
Lacrimal functional unit  
logMAR 
Logarithm of the minimum angle of resolution 
MGD 
Meibomian gland dysfunction 
mm 
Millimeter 
NEI 
National Eye Institute 
OSDI© 
Ocular Surface Disease Index© 
OTC 
Over-the-counter 
PP 
Per protocol 
PRK 
Photorefractive keratectomy 
PROSE 
Prosthetic replacement of the ocular surface ecosystem 
SAE 
Serious adverse event 
SOP 
Standard operating procedure 
TENS 
Transcutaneous electrical nerve stimulation 
UADE 
Unanticipated adverse device effect 
US 
United States 
VAS 
Visual analog scale 
WOCBP 
Women of childbearing potential 
 
 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 10 of 50 
March 10, 2017   
1.0 INTRODUCTION 
1.1 
Background 
The 2007 National Eye Institute (NEI)/Industry Dry Eye Workshop defined dry eye disease 
(DED) as a multifactorial disease of the tears and ocular surface that results in symptoms of 
discomfort, visual disturbance, and tear film instability with potential damage to the ocular 
surface.1 Dry eye disease has a complex pathophysiology and a multifactorial etiology related to 
an inadequacy of one or more layers of the tear film. It is accompanied by increased osmolarity 
of the tear film and inflammation of the ocular surface.1 An estimated 25 million Americans are 
reported to have DED, one of the most common reasons patients seek care with their eye care 
professional.1,2    
Dry eye is recognized as a disturbance of the Lacrimal Functional Unit (LFU), an integrated 
system comprised of the lacrimal glands, ocular surface (cornea, conjunctiva and meibomian 
glands) and lids, and the sensory and motor nerves that connect them.3 This functional unit 
controls the major components of the tear film in a regulated fashion and is responsive to 
environmental, endocrinological, and cortical influences. Its general function is to preserve tear 
film integrity, corneal transparency, and the image quality projected onto the retina.4-6  
Signs of dry eye include reduced tear volume, delayed tear clearance, abnormal tear osmolarity, 
decreased tear film break-up time, punctate keratitis and distorted mires on keratometry or 
corneal topography. Symptoms can include dryness, grittiness, burning, stinging, discomfort, 
photophobia, redness, tearing, reduced ability for prolonged reading or computer work and 
fluctuating vision. These symptoms are typically worse later in the day and can be triggered or 
exacerbated by environmental conditions such as low humidity or wind. 
The severity and prevalence of dry eye in the general population increases with age and is 
particularly common in post-menopausal women and in those 65 and older. While patients with 
mild to moderate DED experience a range of complaints, as described above, patients with 
severe dry eye are at risk for more serious ocular findings, such as punctate keratopathy 
evidenced by significant fluorescein staining of the cornea and epithelial defects. More severely 
affected patients can experience a quality of life deficiency comparable to that of moderate to 
severe angina.7 
Studies suggest that dry eye can be associated with significant impact on visual function, 
including reading and driving4 as well as daily activities, social and physical functioning, 
workplace productivity, and quality of life.5 
1.2 
Current Treatment Options for Dry Eye Disease 
Treatment for dry eye is generally palliative in nature and intended to supplement patients’ 
natural tears or to improve the residence time of a limited volume of tears. Depending on the 
severity of disease and the underlying etiology of the DED, treatment options include artificial 
tear substitutes (solutions, ointments, and gels), punctal plugs, warm compresses, environmental 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 11 of 50 
March 10, 2017   
modification, omega-3 fatty acid supplements, and moisture chamber goggles.8,9 For patients 
with an inflammatory component to their DED, topical cyclosporine (RESTASIS®; Allergan) or 
lifitegrast (Xiidra®; Shire) are treatment options and an eyelid thermal pulsation system 
(Lipiflow Thermal Pulsation System; Tearscience, Inc.) can be used by patients with evaporative 
dry eye or lipid deficient dry eye. Patients with more severe disease may be treated with punctal 
cautery, systemic cholinergic agonists, systemic anti-inflammatory agents, mucolytic agents, 
autologous serum tears, Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE) 
scleral contact lenses and tarsorrhaphy.   
The most commonly used treatment for DED, artificial tear substitutes, have significant 
limitations as therapeutic modalities for this condition. Many artificial tear formulations contain 
preservatives such as benzalkonium chloride, which have been shown to be toxic to the corneal 
epithelium. While preservative-free DED products are commercially available, the risk of 
microbial contamination if improperly stored and the limited time after opening before disposal 
is required make this option less than ideal. 
Punctal plugs are associated with poor retention and complications. A study focused on the time 
course of retention showed that 29% of plugs were lost within the first month of use10 and another 
showed that 56% of silicone plugs were retained after two years.11 Complications include plug 
migration, biofilm formation and infection.12 Punctal plugs that are displaced into the lacrimal 
system may pass through the system, and blockage and secondary infection have been reported.  
Given the limitations of the most commonly available therapies for dry eye (artificial tears and 
punctal plugs), it is not surprising that DED continues to be considered one of the most poorly 
treated diseases in ophthalmology.   
1.3 
Rationale  
The nasolacrimal reflex is a well-established pathway by which nasal stimuli promote both 
resting basal13 and bolus tear secretion. The reflex plays a functional role in expelling foreign 
bodies or irritants from the nose by secreting tears into the nasal cavity via the nasolacrimal duct 
upon stimulation by the irritant.   
Reflex activation of the lacrimal glands is also one of the body’s primary compensatory 
mechanisms for addressing ocular surface dryness. Unfortunately, over time, an arid 
environment and resulting inflammation results in damage to the afferent nerves innervating the 
cornea, compromising the reflex response and ultimately leading to an even drier ocular surface. 
The application of electrical stimulation to sensory neurons of the nasal cavities to acutely 
increase natural tear production in DED is a promising alternative to replenishment and symptom 
reduction with artificial tears and ointment.  

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 12 of 50 
March 10, 2017   
1.4 
Controlled Adverse Environment Model 
The signs and symptoms of dry eye are known to respond to environmental conditions such as 
temperature, relative humidity, air flow, allergens and pollutants.14 Variations in these 
environmental conditions can make the testing of investigational products for the treatment of 
dry eye challenging. In response, models have been developed to control ocular exposure to 
temperature, relative humidity and air flow. By controlling these factors, clinical testing can be 
performed under a more uniform set of conditions. This study utilizes the controlled adverse 
environment (
 model to assess symptoms of dry eye.15 The CAE 
is a room that standardizes environmental conditions by regulating humidity, temperature, 
airflow, lighting conditions and visual tasking. The CAE represents everyday situations16 that 
induce discomfort for dry eye patients such as forced air heating systems, airplane travel and 
computer use and allows for the standardization of these influential factors. As such, the CAE 
has been used in several studies of pharmaceuticals for dry eye.17-19 In this study, dry eye 
participants are exposed to the CAE for up to two hours while symptoms are evaluated before 
and after application of the investigational device.  
1.5 
Proposed Indication 
The TrueTear provides a temporary improvement in dry eye symptoms during neurostimulation 
in adult patients. 
2.0 STUDY OBJECTIVES 
The objective of this study is to characterize acute dry eye symptom relief assessed during 
exposure to a Controlled Adverse Environment (CAE) following use of TrueTear for 45 days. 
3.0 CLINICAL HYPOTHESES 
After 45 days of TrueTear use, neurostimulation continues to result in a statistically significant 
reduction in eye dryness as exacerbated by exposure to the CAE. 
4.0 OVERALL STUDY DESIGN 
This is a prospective, single-arm, open-label study conducted at up to two sites in the US, 
designed to characterize acute dry eye symptom relief following 45 days of use of the TrueTear 
device in adult participants with DED. Approximately 60 male and female participants at least 
22 years of age with a participant-reported history of dry eye in both eyes and meeting all other 
study eligibility criteria will use the TrueTear on a daily basis and during CAE exposure. 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 13 of 50 
March 10, 2017   
 
5.0 STUDY POPULATION 
5.1 
Number of Participants 
It is estimated that approximately 125 participants will be screened at up to two sites in 
the US to achieve approximately 60 qualified participants.  
5.2 
Study Population Characteristics  
All participants should meet all inclusion criteria and none of the exclusion criteria. 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 14 of 50 
March 10, 2017   
5.3 
Inclusion Criteria 
Participants should: 
1. Be at least 22 years of age at the Screening Visit 
2. Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 
months prior to the Screening Visit 
3. 
 
4. 
 
 
 
 
 
 
5. 
 
6. Be literate, able to speak English, and able to complete questionnaires independently 
7. 
 
8. 
 
5.4 
Exclusion Criteria 
Participants should not: 
1. 
 
  
2. Have chronic or recurrent epistaxis, coagulation disorders or other conditions that, in the 
opinion of the Investigator, may lead to clinically significant risk of increased bleeding 
3. Have had nasal or sinus surgery (including history of application of nasal cautery) or 
significant trauma to these areas  
4. 
 
 
5. 
 
 
6. Have had a corneal transplant in either or both eyes 
7. Have used contact lenses within 7 days prior to the Screening Visit or anticipate the use 
of contact lenses at any time during the study  

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 15 of 50 
March 10, 2017   
8. 
 
 
9. 
 
 
 
 
meibomian gland disease that are typically associated with 
dry eye disease are allowed. 
10. Have a cardiac demand pacemaker, implanted defibrillator, or other active implanted 
metallic or active implanted electronic device in the head  
11. 
 
 
   
12. 
 
 
13. 
  
 
  
 
 
 
 
   
 
    
14. Be a female who is pregnant, nursing an infant, or planning a pregnancy during the 
duration of the study  
15. Be currently enrolled in an investigational drug or device study or have used an 
investigational drug or device within 30 days prior to the Screening Visit 
5.5 
Inclusion/Exclusion Exceptions 
The investigator has the right to exclude a potential participant’s enrollment in the study if s/he 
deems it in the best interest of the participant. Reasons for exclusion on this basis will be 
recorded.   
5.6 
Discontinuation Criteria (if applicable) 
Participants are free to discontinue their participation in this study at any time and for any 
reason, specified or unspecified, without prejudice. In addition, the Investigator may decide to 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 16 of 50 
March 10, 2017   
discontinue a participant from the study for safety reasons or when it is in the best interest of the 
participant. No constraints will be placed on ordinary patient management.  
Reasons for participant withdrawal may include but are not limited to the following: 
• 
Either at the Investigator's request, for safety reasons (e.g., serious or severe 
AE), or at the participant’s request 
• 
Non-compliance (e.g., failure to follow application instructions, missing visits, 
using prohibited medications) 
• 
When a concomitant therapy likely to interfere with the results of the study is 
reported or required by the participant (the Investigator will report all such 
information on the source documents/ case report forms (CRFs) and decide, in 
accordance with the Sponsor, whether the participant is to be withdrawn) 
• 
A confirmed positive pregnancy test at any time during the study 
• 
When a participant is lost to follow-up. The Investigator (or designee) will 
attempt three times to reach the participant by telephone, and will send a 
follow-up letter by certified mail before considering the participant as lost to 
follow-up. These actions will be documented and recorded on the End of Study 
CRF and a copy of the follow-up letter maintained in the Investigator's file. 
• 
When a participant is erroneously admitted into the study or does not meet the 
eligibility criteria 
In addition, the Sponsor also reserves the right to discontinue the study at any time for clinical or 
administrative reasons. 
All early discontinuations and their reasons should be carefully documented by the Investigator 
on the End of Study CRF and, if applicable, on the Adverse Event (AE) CRF. Notification of a 
participant’s discontinuation and the reason for discontinuation will be made to 
and/or 
Sponsor. No participant who has entered the CAE at Day 0 can be replaced by another 
participant if the participant is discontinued prematurely for any reason. Participants who 
terminate early will be asked to complete safety assessments (if the participant agrees) prior to 
study exit. 
6.0 STUDY PARAMETERS 
6.1 
Effectiveness Measures 
 
Primary Effectiveness Measure 
6.1.1
The visual analog scale (VAS) has frequently been used for the collection of patient-
reported outcomes and has been commonly used to assess dry eye symptoms in clinical 
studies.20-29 As such, the 2007 report of the International Dry Eye WorkShop (DEWS) 
listed the Visual Analog Scale as a well-defined symptom assessment methodology 
suitable for use in dry eye clinical trials.30 Patient-reported outcomes assessed using the 
Eye Dryness Score (EDS) VAS have been used in other dry eye studies and were 
recently used as the primary symptom endpoint for FDA approval of lifitegrast (Xiidra®) 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 17 of 50 
March 10, 2017   
for the treatment of the signs and symptoms of dry eye disease.31,32,33 Based on this 
information, the EDS visual analog scale was selected as the primary effectiveness 
variable to provide a direct assessment of the participant’s perception of their current eye 
dryness symptoms. 
The primary effectiveness measure will be the change in dry eye symptom severity score 
during CAE exposure at Study Day 45 assessed using the EDS. The EDS will be 
assessed using a self-administered VAS every five minutes during CAE exposure. The 
analysis variable will be the change in EDS values from the last time point prior to 
application administration to the subsequent time point following administration. The 
primary effectiveness analysis will compare the change in EDS between the pre-
application and post-application scores to an expected change of 0. The test will be one-
sided and evaluated at an α of 0.025 in the Full Analysis Set (FAS) population. 
 
 
6.1.1
 
 
  
 
 
     
6.2 
Safety Measures 
 
6.3 
Other Measures 
 
 
 
 
 
 
7.0   DEVICE DESCRIPTION 
The TrueTear device delivers small electrical currents to the inner cavity of the nose, activating 
nerves that stimulate the body’s natural tear production system. 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 18 of 50 
March 10, 2017   
The device consists of four distinct parts (Figure 1): 
1. A reusable Base Unit which produces the electrical stimulation waveform. 
2. A disposable Tip that inserts into the nasal cavity and stimulates the target intranasal 
tissue. 
3. A reusable Cover to protect the Tip.  
4. A Charger which recharges the battery inside the Base Unit. 
 
       
 
 
 
 
 
 
 
 
 
 
 
Figure 1  The TrueTear system components 
TrueTear System 
Base Unit with Disposable Tips (Front and Back) 
Base Unit with Cover 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 19 of 50 
March 10, 2017   
 
Base Unit 
7.1.1
When activated, the Base Unit provides electrical pulses to the Tip. The strength of these 
pulses is controlled by two buttons, with five different intensity levels available, indicated 
by the number of illuminated LEDs on the Base Unit. The device internally records the time 
and duration of device use.   
 
Disposable Tip  
7.1.2
The disposable Tip is specially designed to allow the participant to easily apply stimulation 
to the target areas within the nose. The Tip attaches to the Base Unit and contains hydrogel 
(similar to the material used in contact lenses) that contacts the inside of the nose to provide 
stimulation. Each tip may be used up to 24 hours. After 24 hours, the used tip should be 
discarded and a fresh tip should be attached. A separate Cover can be used to protect the Tip 
and Base Unit when the device is not in use. 
 
Cover 
7.1.3
The Cover may be placed over the top of the Tip attached to the Base Unit for protection in 
between uses. 
 
Charger 
7.1.4
The Base Unit may be recharged by removing the Tip and placing the Base Unit onto the 
Charger. Charging typically takes under 4 hours, and a green LED indicates that the process 
has completed.  
7.2 
Device Accountability 
Each Base Unit has a unique serial number and the serial number of the Base Unit used by each 
participant will be recorded on the appropriate case report form and device accountability log. 
The disposable Tip is provided in a sealed pouch, which is labeled with a lot number and 
expiration date. The lot number of the Tips provided to a participant will also be recorded on the 
appropriate case report forms and on the device accountability log. Tips should not be used 
beyond the expiration date provided on the pouch.   
7.3 
Other Study Supplies 
The following will be provided by the Investigator: 
• Urine pregnancy test kits 
• Schirmer test strips 
• Fluorescein sodium solution or fluorescein strips 
• Proparacaine 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 20 of 50 
March 10, 2017   
8.0 STUDY METHODS AND PROCEDURES 
8.1 
Participant Entry Procedures 
 
Overview 
8.1.1
Participants as defined by the criteria in section 5.2, 5.3, and 5.4 will be considered for entry 
into this study. 
 
Informed Consent 
8.1.2
Prior to a participant’s participation in the trial (i.e., prior to study-related procedures), the 
study will be discussed with each potential participant and participants wishing to 
participate should give written informed consent using an IRB approved informed consent 
form (ICF). The ICF should be the most recent version that has received approval by a 
properly constituted Institutional Review Board (IRB). 
 
Washout Intervals and Prohibited Treatments 
8.1.3
Prohibited treatments and activities are outlined in the Exclusion Criteria and include: 
• 
Contact lenses – 7 days prior to the Screening Visit and throughout study 
duration 
• 
Punctal or intracanalicular plugs – Throughout study duration 
Medications or dry eye products prohibited as follows: 
• 
Ophthalmic prescription or OTC eye medications (eye drops, gels, or 
ointments) or dry eye products on the day of and for duration of Visit 1, Visit 2, 
Visit 3 and Visit 4. Participants may use such products as needed at the 
completion of each study visit. 
• 
Nasal sprays within 4 hours of and for the duration of Visit 1, Visit 2, Visit 3 
and Visit 4  
• 
Use of TrueTear on the day of Visit 2, Visit 3 and Visit 4 (application of 
TrueTear at Visit 2 and Visit 4 will be performed in the CAE) after which 
participants may perform additional applications as needed  
 
Procedures for Final Study Entry 
8.1.4
Participants should meet all inclusion and none of the exclusion criteria. 
 
Methods for Assignment of Participant Number 
8.1.5
At the Screening Visit, participants who provide written informed consent will be assigned a 
unique 5-digit screening number, which includes the 2-digit site number plus a unique 3-
digit screening number beginning with 001 (e.g., 11001, 11002, 11003, etc.). Screening 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 21 of 50 
March 10, 2017   
numbers should be assigned in ascending consecutive order. Participants who meet all of the 
eligibility criteria will be scheduled to return for the Day 0 Visit.   
8.2 
Participant Training, Device Dispensing, and Home Use 
On Day 0, participants will be provided with a TrueTear and disposable tips to take home with 
them and use daily per the Instructions for Use (IFU). Participants will receive training to 
perform intranasal neurostimulation and will receive a user guide. Following device training and 
prior to entering the CAE, devices for home use will be dispensed to participants. The serial 
number of the unit and the lot number of disposable tips will be documented in the participant’s 
CRF.    
Participants will undergo stimulation for the first time on Day 0 during the CAE session where 
they will be instructed to apply stimulation for approximately three minutes. Training will 
include instruction on the following points:  
• Between study visits, participants will be asked to perform neurostimulation at least two 
times per day up to as many as 10 times per day, as needed. Each stimulation should last no 
longer than three minutes. Participants should be instructed that the device has a single-day 
stimulation limit of 30 minutes at which point the device will time-out. 
• Participants will be asked to fully charge the device before first use and to re-charge daily. 
• After using the device, participants will be instructed to clean the system with tissue or an 
alcohol pad if necessary prior to placing the cover to protect the tip between uses.  
• Participants should be instructed to replace the disposable tip daily according to the IFU and 
that the used tip should be discarded in trash. 
For the device application, participants will be instructed to place the tips of the TrueTear into 
both nostrils simultaneously towards the top and front of the nose (as in Figure 2). They will be 
told to turn on the unit by holding down the + button for approximately two seconds. There are 
five stimulation intensity levels and participants may adjust the level by pressing the + or – 
buttons to obtain a gentle tingling sensation. Participants will be told they can cease stimulation 
by holding down the – button for approximately two seconds on the base unit or by withdrawing 
the tips from the nostrils. Participants will be instructed to replace the Tip if they do not feel any 
sensation.  
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 22 of 50 
March 10, 2017   
 
 
Figure 2  Use of the TrueTear 
          (L) Starting position and (R) Correct application position by inserting the disposable 
tips fully into the nasal cavity and to the front of the nose.  
 
At Visit 3 (Day 7), prior to in-office application and evaluation of tear secretion, trained clinical 
personnel will review procedures for the proper use of the device (e.g., correct positioning 
intranasally, frequency and duration of use, daily replacement and disposal of tips, etc.) with 
participants. 
Note: A Sponsor representative may be present at visits to assist in training participants on the 
use of the device.   
8.3 
Concurrent Therapies 
The use of any concurrent medication, prescription or OTC, is to be recorded on the participant’s 
CRF along with the reason the medication was taken. Concomitant medications that are 
considered necessary for the participant’s welfare, but will not interfere with study assessments 
and evaluations, will be allowed during the study at the Investigator’s discretion. 
Concurrent enrollment in another investigational drug or device study is not permitted. 
8.4 
Examination Procedures 
The following procedures will be performed (see Appendix 2 for description): 
 
Procedures to be Performed at the Screening Visit (Visit 1; Day -21 ± 20)  
8.4.1
Review of qualification criteria should take place with each test that relates to eligibility. 
• 
 
 
 
 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 23 of 50 
March 10, 2017   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Procedures to be Performed on the Day 0 CAE Visit (Visit 2; Day 0)) 
8.4.2
 
 
 
 
 
 
 
 
 
 
  
• 
Approximately 120 minutes of CAE exposure 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 24 of 50 
March 10, 2017   
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
Procedures to be Performed on Tear Production Assessment Visit (Visit 3; 
8.4.3
Day 7 ± 2)  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Procedures to be Performed on Day 45 CAE Visit (Visit 4; Day 45 ± 7) 
8.4.4
• 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 25 of 50 
March 10, 2017   
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
Early Termination/Discontinuation 
8.4.1
If a participant is discontinued from the study prior to Visit 4, then all safety evaluations and 
Pre-CAE evaluations that are to be performed should be completed on the day of 
discontinuation (early termination) with the participant’s agreement. 
8.5 
Schedule of Visits 
 
Scheduled Visits 
8.5.1
Participants will remain in the study for approximately 66 days and will be seen at the 
following intervals: 
Visit 1 
Screening Visit (Day -21 ± 20) 
Visit 2 
Day 0 CAE Visit (Day 0) 
Visit 3 
Tear Production Assessment Visit (Day 7 ± 2) 
Visit 4 
Day 45 CAE Visit (Day 45 ± 7) 
 
The schedule of exams and procedures performed at these visits can be found in Appendix 
1. Descriptions of exams and procedures performed during these visits can be found in 
Appendix 2. 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 26 of 50 
March 10, 2017   
Participants who are exited from the study due to unanticipated adverse device effects 
(UADEs) will be followed until their medical outcome is determined. The Investigator 
should provide written reports about the status of UADEs to the study Sponsor. 
 
Unscheduled Visits 
8.5.2
These visits may be performed in order to ensure participant safety. For participants 
reporting for an unscheduled visit, assessments performed are at the discretion of the 
Investigator. At minimum, AEs should be assessed. All procedures performed at an 
unscheduled visit will be recorded on the Unscheduled Visit CRF. Any procedure indicated 
in the CRF that is not performed should be indicated as “Not done.” 
8.6 
Completed Participants 
A completed participant is one who has not been discontinued from the study and has 
successfully completed Visit 4. 
8.7 
Study Termination 
The study may be stopped at any time by the Investigator, the Sponsor, and/or 
with 
appropriate notification. 
8.8 
Study Duration 
An individual participant’s participation will involve up to four visits over an approximate 66 
day period. 
8.9 
Monitoring and Quality Assurance 
 
Study Monitoring 
8.9.1
Allergan personnel (or designees) will monitor this study in a manner consistent with 
applicable health authority regulations and the procedures adopted by the SOPs of the 
Sponsor, Allergan. Prior to the start of the study, member(s) of Allergan and/or 
 (or 
designees) will review the protocol, CRFs, regulatory obligations, and other material or 
equipment relevant to the conduct of the study with the Principal Investigator/Sub-
Investigator(s) and pertinent study staff. Monitoring visits will occur as necessary during the 
course of the investigation to verify: 
• 
The rights and well-being of participants are protected 
• 
The conduct of the investigation is in compliance with the currently approved 
protocol/amendment, GCP and IRB/IEC requirements 
• 
The integrity of the data 
• 
Study device accountability  
• 
Adequate study documentation 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 27 of 50 
March 10, 2017   
During the course of the study, if the Sponsor (or designee) determines that the Investigator 
is non-compliant with the study plan and/or applicable regulatory requirements, the Sponsor 
(or designee) will take written action to correct the non-compliance and to secure 
compliance. In addition, the Sponsor (or designee) may terminate the Investigator’s 
participation in the study if appropriate, or if the Investigator remains non-compliant despite 
the Sponsor’s actions. This termination will be documented in a memo or follow-up letter to 
the Principal Investigator. 
 
Recording of Data  
8.9.1
Participant data recorded on CRFs during the study will be documented in an anonymous 
fashion. The participant will only be identified by the participant number. If, as an 
exception, it is necessary for safety or regulatory reasons to identify the participant, the 
Sponsor or its representatives, and the Investigator, are bound to keep this information 
confidential. 
9.0 ADVERSE EVENTS  
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory 
finding) symptom, or disease temporally associated with the use of an investigational product but 
not necessarily related to the investigational product. An AE may also be called a complication. 
The capture of AEs will begin with the participant’s entry into the CAE. 
9.1 
Adverse Event Recording 
All AEs spontaneously reported by the participant and/or in response to an open question from 
study personnel or revealed by observation, physical examination or other diagnostic procedures 
will be recorded on the appropriate pages of the CRF. Any clinically relevant deterioration in 
clinical finding is considered an AE and should be recorded. When possible, signs and symptoms 
indicating a common underlying pathology should be noted as one comprehensive event. 
9.2 
Adverse Event Evaluation 
The Investigator should evaluate if each AE is serious, related to the investigational device and 
anticipated using the following definitions. 
A serious adverse event (SAE) is defined as any untoward medical occurrence that: 
• 
It results in death (i.e., the AE actually causes or leads to death); 
• 
It is life threatening (i.e., the AE places the participant at immediate risk of 
death); 
• 
It requires or prolongs inpatient hospitalization. If a participant is hospitalized 
to undergo a medical or surgical procedure as a result of an AE, the event 
responsible for the procedure, not the procedure itself, should be recorded as 
the event.  For example, if a participant is hospitalized to undergo coronary 
bypass surgery, the heart condition that necessitated the bypass should be 
recorded. Hospitalizations for diagnostic or elective surgical procedures or 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 28 of 50 
March 10, 2017   
hospitalizations required to allow outcome measurement for the study should 
not be recorded as SAEs: 
• 
It results in persistent or significant disability/incapacity (i.e., the AE results in 
substantial disruption of the participant’s ability to conduct normal life 
functions); 
• 
It results in a congenital anomaly/birth defect in a neonate/infant born to a 
mother exposed to the investigational device; 
• 
It is considered a significant medical event by the investigator based on medical 
judgment (e.g. may jeopardize the participant or may require medical/surgical 
intervention to prevent one of the outcomes listed above); 
• 
It is considered sight-threatening by the Investigator. 
9.3 
Relationship of the AE to the investigational device 
Definite 
A clear cut causal relationship with the study device 
and no other possible cause 
Probable 
A causal relationship with the study device is likely 
although alternate etiologies are also possible  
Possible 
A causal relationship with study device is not 
definite, alternate etiologies are also possible 
Not related 
The AE has no causal relationship to study device 
and/or there is evidence of alternative etiology such 
as concurrent medication or illness. 
Not 
applicable 
The participant has not been exposed to the study 
device. 
The AE will be determined to be device-related, making it an adverse device effect (ADE), if it 
is identified to have had a definite, probable or possible causal relationship to the investigational 
device. 
An AE is unanticipated if the nature, severity, or frequency of the event is not consistent with 
either the known or foreseeable risk of AEs associated with the procedures involved in the 
research that are described in (a) the protocol-related documents, such as the IRB-approved 
research protocol, user manuals and the current IRB-approved informed consent document, and 
(b) other relevant sources of information such as product labeling and package inserts; or the 
expected natural progression of any underlying disease, disorder, or condition of the 
participant(s) experiencing the AE and the participant’s predisposing risk factor profile for the 
AE. 
9.4 
Serious and Unanticipated Adverse Device Effects 
A serious and unanticipated adverse device effect is defined as “any serious adverse effect on 
health or safety or any life-threatening problem or death caused by, or associated with, a device 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 29 of 50 
March 10, 2017   
if that effect, problem, or death was not previously identified in nature, severity, or degree of 
incidence in the investigational plan, or any other unanticipated serious problem associated with 
a device that relates to the rights, safety or welfare of participants.” 
9.5 
Adverse Event Reporting 
All AEs that occur during the course of the study should be reported on the Adverse Event CRF. 
The Investigator should determine the intensity of the event. 
Mild 
Awareness of sign or symptom, but easily tolerated  
Moderate 
Discomfort enough to cause interference with 
normal daily activities  
Severe 
Inability to perform normal daily activities 
All SAEs and ADEs should be reported by the Investigator to 
 and the Sponsor in 
writing within 24 hours from the point in time when the Investigator becomes aware of the event. 
It is the responsibility of the Investigator to promptly notify the Institutional Review Board (IRB) 
of all unanticipated SAEs and unanticipated problems, per the IRBs reporting requirements.  
Throughout the course of the proposed study, all efforts will be made to remain alert to possible 
adverse experiences or untoward findings. If adverse experiences occur, the first concern will be 
the safety and welfare of the participant. Appropriate medical intervention will be made.   
 and the Sponsor will immediately conduct an evaluation of any UADE. The results of 
the evaluation will be reported to the IRB within 10 days of 
 and/or the Sponsor 
becoming aware of the event. If it is determined by 
and the Sponsor to present an 
unreasonable risk to study participants, all investigations or parts of the investigation presenting 
that risk will be terminated as soon as possible. Termination will occur not later than five 
working days after 
 and the Sponsor makes this determination, and not later than 15 
working days after first receiving notice of the event. 
 and the Sponsor will not resume 
an investigation terminated under these conditions without an additional IRB approval.  
Contact information for reporting Serious Adverse Events: 
 
 
 
 
 
 
 
 
 
 
 
Sponsor Contact Information 
 
 
 
 
 
 
 
 
 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 30 of 50 
March 10, 2017   
Office Facsimile: 
650-737-0200 
9.6 
 Anticipated Adverse Events 
The following is a list of potential AEs associated with the use of the device:  
• 
Nasal discomfort or pain 
• 
Epistaxis 
• 
Excessive sneezing    
• 
Nasal irritation, paresthesia or numbness post-stimulation 
• 
Nasal infection, abrasion or inflammation 
• 
Skin irritation or hypersensitivity 
• 
Headache (e.g., tension, migraine, etc.)  
• 
Facial pain 
• 
Excessive salivation 
• 
Sensation of teeth vibrating 
• 
Excessive rhinorrhea 
• 
Temporary aggravation of nasal allergies 
• 
Allergic reaction to contact materials 
The following is a list of potential AEs associated with the testing procedures at Screening or 
with CAE exposure: 
• 
Ocular discomfort 
• 
Moderate or severe conjunctival injection 
• 
Clinically significant decrease in visual acuity  
• 
Clinically significant increase in corneal or conjunctival epithelial defects 
• 
With use of proparacaine, temporary burning, stinging and conjunctival redness 
of the eyes 
• 
With use of proparacaine, a rare hyperallergic corneal reaction characterized by 
epithelial keratitis, sloughing of epithelium, corneal filaments and iritis 
• 
With the Schirmer test, corneal irritation and abrasion  
• 
Allergic reaction to contact materials 
10.0 PREGNANCY 
Women of Childbearing Potential (WOCBP) include any females who have experienced 
menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral 
tubal ligation or bilateral oophorectomy) or are not postmenopausal at least 12 months since last 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 31 of 50 
March 10, 2017   
menses. WOCBP will be required to use designated methods of birth control during the course of 
the study. All women who are pregnant, nursing an infant, or planning a pregnancy during the 
duration of this study will be excluded from participation.  
If a participant or Investigator suspects that the participant may be pregnant prior to study device 
administration, the study device should be withheld until the results of pregnancy testing are 
available. If pregnancy is confirmed, the participant should not administer the study device and 
should not be enrolled in the study. 
If a female participant becomes pregnant during the study, the Investigator will notify Allergan 
(or designee) immediately after the pregnancy is confirmed. The Investigator will (1) obtain a 
consent from the female participant for pregnancy follow-up and (2) follow the progress of the 
pregnancy to term.  The Investigator should document the outcome of the pregnancy and 
provide a copy of the documentation to Allergan (or designee). 
11.0 STATISTICAL HYPOTHESIS AND METHODS OF ANALYSES 
11.1 
Power Calculation and Determination of Sample Size 
In a previous controlled study assessing the change in EDS while in the CAE at Day 0, the 
observed mean (SD) treatment difference for the TrueTear device compared to the control 
was -13.4 (23.9).  It is unknown what, if any, effect on the change in EDS while in the CAE will 
be with the TrueTear device application after 45 days of use. Using an estimated standard 
deviation of 25, 45 participants will provide over 90% power to detect a EDS reduction of 13 
based on a one-sided test at an α of 0.025. 
In the previous study, approximately 10% of the participants did not reach the application 
threshold during the CAE session. In order to allow for participants that discontinue the study 
before Day 45 or do not reach the application threshold in the CAE, approximately 60 qualified 
participants will be identified to initiate the study to ensure Day 45 results for 45 participants. 
11.2 
Statistical Hypotheses and Level of Significance 
The null hypothesis is, after 45 days of TrueTear use, neurostimulation fails to result in a 
statistically significant reduction in EDS exacerbated by exposure to the CAE. 
The alternative hypothesis is, after 45 days of TrueTear use, neurostimulation will result in a 
statistically significant reduction in EDS exacerbated by exposure to the CAE. 
The hypothesis can be expressed as: 
H0: Δ ≤ 0 mm 
HA: Δ > 0 mm 
where Δ represents the change in EDS score, symptom relief, from the TrueTear application. 
Statistical tests for the primary and exploratory effectiveness variables will be one-sided and 
evaluated at an α of 0.025. 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 32 of 50 
March 10, 2017   
11.3 
Randomization 
This study is not randomized. 
11.4 
Evaluability of Data 
All participants who initiated at least one study application will be eligible for inclusion in the 
analyses. Participation in the study will be summarized by presenting the number of participants 
who were enrolled, the number of participants who completed the study, and the number of 
participants who did not complete the study due to not reaching the threshold or by reason of 
early discontinuation. 
Full Analysis Set Population (FAS): The FAS population will include all participants who 
initiated at least one application of the TrueTear device at any point during the study.  
Per protocol population (PP): The PP population is a subset of the FAS population, which did not 
have a major protocol deviation likely to seriously affect the primary outcome of the study. This 
population will be the secondary population for the effectiveness analyses and will also be used 
to summarize the primary and exploratory effectiveness variables. If the PP and FAS populations 
are exactly the same, then additional efficacy analyses on the PP population will not be 
performed.   
Safety Population: The safety population will be the same as the FAS population. 
11.5 
General Statistical Considerations 
Statistical analyses will use a two-tailed test and will be evaluated at an α of 0.05 unless 
otherwise specified. The mean, standard deviation (SD), median, minimum and maximum will 
be presented for continuous variables such as participant age. For categorical variables, such as 
sex, the number for each category, the total number evaluated, and the percentage will be 
presented. 
11.6 
Participant Accountability and Missing Data 
Participants who withdraw from the study will be tabulated with the reasons for the withdrawal. 
A sensitivity analysis of the FAS population will only be conducted if ≥ 5% of the primary 
effectiveness results are missing. The imputation method is described below in the Effectiveness 
Analyses section. Missing data will not be imputed for the PP or Safety populations. 
11.7 
Participant Demographic and Baseline Characteristics 
The demographic and baseline characteristics of the study population observed will be presented 
descriptively.   
11.8 
Effectiveness Analyses 
The primary effectiveness variable will be the change in EDS between the time point preceding 
application and the subsequent time point following application. The primary effectiveness 
endpoint will be the analysis of the primary effectiveness variable for the FAS population at Day 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 33 of 50 
March 10, 2017   
45 without imputation. The analysis will use a paired t-test or Wilcoxon signed-rank test, as 
appropriate, and will be evaluated at a one-sided α of 0.025. If ≥ 5% of the FAS population is 
missing the primary effectiveness variable at Day 45, a sensitivity analysis of EDS difference at 
Day 45 will be performed by imputing the missing EDS difference as zero. Study participants 
with a missing Day 45 result will be imputed one at a time and the analysis will be repeated. This 
process will continue until either the result is no longer statistically significant or all participants 
with missing results have been imputed. As an additional sensitivity analysis, missing values will 
be imputed using a random selection process from the available Day 45 results and the analysis 
will be repeated. This process will be performed 10 times and a single combined p-value for the 
10 imputations will be obtained by a method described in Rubin38 and in the SAS manual for 
PROC MIANALYZE.39  If the study includes more than one site, summaries of the primary 
effectiveness endpoint without imputation will be presented by site. 
The primary effectiveness analysis will be repeated in the PP population as a sensitivity analysis. 
The exploratory effectiveness variables will be the difference in EDS at Day 0, the difference in 
dry eye discomfort using the 
Calibra scale in the FAS population at Day 0 and Day 45 and 
the difference in Schirmer test results at Day 7. The analysis will be performed using the same 
method as the primary effectiveness variable. Statistical significance will be determined using a 
one-sided test at an α of 0.025.  
11.9 
Safety Analyses 
The safety analyses will be performed for the Safety population. The primary safety endpoint 
will be the proportion of participants who experience one or more device-related AEs for each 
application and overall. The proportion and exact 95% confidence interval will be computed. 
Any changes in corrected distance visual acuity or slit lamp biomicroscopy findings will be 
summarized. 
12.0 FINAL CLINICAL STUDY REPORT 
A final clinical study report will be prepared after completion of the study. 
13.0 COMPLIANCE WITH GOOD CLINICAL PRACTICES, ETHICAL 
CONSIDERATIONS, AND ADMINISTRATIVE ISSUES 
13.1 
Protection of Human Participants 
 
Participant Informed Consent 
13.1.1
Informed consent should take place before any study-specific procedures are initiated. Signed 
and dated written informed consent should be obtained from each participant and/or from the 
participant’s parent or legal guardian prior to enrollment into the study. 
All ICFs should be approved for use by the Sponsor and receive approval/favorable opinion from 
an IRB prior to use. If the consent form requires revision (e.g., due to a protocol amendment or 
significant new safety information), it is the Investigator’s responsibility to ensure that the 
amended informed consent is reviewed and approved by Sponsor and 
 prior to submission to 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 34 of 50 
March 10, 2017   
the governing IRB and that it is read, signed and dated by all participants subsequently enrolled 
in the study as well as those currently enrolled in the study if required by the governing IRB. 
If informed consent is taken under special circumstances (oral informed consent), then the 
procedures to be followed should be determined by 
and/or study Sponsor and provided in 
writing by 
 and/or study Sponsor prior to the consent process. 
 
Institutional Review Board (IRB) Approval 
13.1.2
This study is to be conducted in accordance with IRB regulations (U.S. 21 Code of Federal 
Regulations [CFR] Part 56.103). The Investigator should obtain appropriate IRB approval before 
initiating the study and re-approval at least annually. 
 
Ethical Conduct of the Study 
13.1.3
This study will be conducted in compliance with the protocol, Good Clinical Practices (GCPs), 
including the International Conference on Harmonisation (ICH) Guidelines, and the ethical 
principles that originated with the Declaration of Helsinki. 
 
Participant Confidentiality 
13.1.4
All personal study participant data collected and processed for the purposes of this study should 
be maintained by the Investigator and his/her staff with adequate precautions to ensure that the 
confidentiality of the data is in accordance with local, state, and federal laws and regulations. 
Monitors, auditors and other authorized representatives of 
 the Sponsor, the IRB approving 
this study, the Food and Drug Administration (FDA), the Department of Health and Human 
Services (DHHS), and other domestic government agencies, will be granted direct access to the 
study participant’s original medical and study records for verification of the data and/or clinical 
trial procedures. Access to this information will be permitted to the aforementioned individuals 
to the extent permitted by law. 
A report of the results of this study may be published or sent to the appropriate health authorities 
in any country in which the study device may ultimately be marketed, but the participant’s 
identity will not be disclosed in these documents. 
13.2 
Documentation 
Source documents may include a participant’s medical records, hospital charts, clinic charts, the 
Investigator’s study participant files, as well as the results of diagnostic tests such as X-rays, 
laboratory tests, and electrocardiographs. The Investigator’s copy of the CRFs serves as the 
Investigator’s record of a participant’s study-related data. 
 
Retention of Documentation 
13.2.1
All study-related correspondence, participant records, consent forms, record of the 
distribution and use of all study device and copies of CRFs should be maintained on file for 
at least two years after the last approval of a marketing application in an ICH region and 
until there are no pending or contemplated marketing applications in an ICH region; or until 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 35 of 50 
March 10, 2017   
at least two years have elapsed since the formal discontinuation of clinical development of 
the study device. These documents will be retained for a longer period if required by the 
applicable regulatory requirements or by an agreement with the Sponsor. It is the 
responsibility of the Sponsor to inform the Investigator/institution as to when these 
documents no longer need to be retained. 
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping study records, custody should be transferred to a person who will 
accept the responsibility. The Sponsor should be notified in writing of the name and address 
of the new custodian. 
13.3 
Regulatory Status 
A previous version of the TrueTear (formerly known as the Oculeve Intranasal Lacrimal 
Neurostimulator) received CE Mark on December 22, 2014 (CE 615662). It has been approved 
for marketing in Canada and Australia as well. It is an investigational device in the US. 
13.4 
Labeling, Packaging, Storage, Accountability, and Return or Disposal of 
Study Device 
All investigational devices will be clearly labeled “For Investigational Use Only.” A device 
accountability log recording the distribution and return of all devices will be maintained by the 
site and will be filed in the Trial Master File. Used disposable tips should be discarded after use; 
unused disposable tips should be returned to the Sponsor at the conclusion of the study. 
13.5 
Recording of Data on Source Documents and Case Report Forms (CRFs) 
All participant data will be captured in the participant CRFs (i.e. source document). The 
Investigator is responsible for ensuring that study data is completely and accurately recorded on 
each participant’s CRF and all study-related materials. All study data should also be attributable, 
legible, contemporaneous, and original. Recorded datum should only be corrected in a manner 
that does not obliterate, destroy, or render illegible the previous entry (e.g., by drawing a single 
line through the incorrect entry and writing the revision next to the corrected data). An individual 
who has corrected a data entry should make clear who made the correction and when, by adding 
to the correction his/her initials as well as the date of the correction. 
13.6 
Amendments to the Protocol 
Any amendment containing major modifications (particularly if it may involve an increased risk 
to the participants) should be approved by the IRB before it may be implemented. No change in 
the conduct of the study can be instituted without written approval from the Sponsor. 
13.7 
Publications 
Information collected during this clinical study concerning TrueTear and results of the data 
obtained are proprietary and strictly confidential. The Sponsor reserves all rights to any such 
information. Authorship and manuscript composition will reflect cooperation among all parties 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 36 of 50 
March 10, 2017   
involved in the study. Authorship will be established before writing the manuscript. Sponsor and 
will have the final decision regarding the manuscript and publication. 
14.0 REFERENCES 
1. 
DEWS. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee 
of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:93-107. 
2. 
Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome: a Delphi approach to 
treatment recommendations. Cornea 2006;25:900-7. 
3. 
Stern ME, Beuerman RW, Fox RI, Gao J, Mircheff AK, Pflugfelder SC. The pathology 
of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998;17:584-
9. 
4. 
Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a 
twenty-five-year review. Cornea 2000;19:644-9. 
5. 
RW B, A M, SC P, ME S. The Lacrimal Functional Unit. In: Pflugfelder SC, Beuerman 
RW, ME S, eds. Dry Eye and Ocular Surface Disorders. New York: Marcel Dekkar; 2004. 
6. 
Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal 
functional unit in the pathophysiology of dry eye. Experimental eye research 2004;78:409-16. 
7. 
Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W. Utility 
assessment among patients with dry eye disease. Ophthalmology 2003;110:1412-9. 
8. 
AAO. Preferred Practice Patterns: Dry Eye Syndrome. 2008. 
9. 
DEWS. Management and therapy of dry eye disease: report of the Management and 
Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007;5:163-
78. 
10. 
Sakamoto A, Kitagawa K, Tatami A. Efficacy and retention rate of two types of silicone 
punctal plugs in patients with and without Sjogren syndrome. Cornea 2004;23:249-54. 
11. 
Horwath-Winter J, Thaci A, Gruber A, Boldin I. Long-term retention rates and 
complications of silicone punctal plugs in dry eye. Am J Ophthalmol 2007;144:441-4. 
12. 
Sugita J, Yokoi N, Fullwood NJ, et al. The detection of bacteria and bacterial biofilms in 
punctal plug holes. Cornea 2001;20:362-5. 
13. 
Gupta A, Heigle T, Pflugfelder SC. Nasolacrimal stimulation of aqueous tear production. 
Cornea 1997;16:645-8. 
14. 
MB A, GW O, LA N, TB E. Dry eye syndromes: diagnosis, clinical trials and 
pharmaceutical treatment – “improving clinical trials.”. In: Sullivan DA SM, Tsubota K, Dartt 
DA, Sullivan RM, Bromberg BB, ed. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. 
New York, NY: Kluwer Academic/Plenum Publishers; 2003. 
15. 
Ousler G, Johnston P, Welch D, Lane K, Abelson M. Validation of the enhanced 
controlled adverse environment II. Invest Ophthalmol Vis Sci 2011;52:3857. 
16. 
Ousler GW, Gomes PJ, Welch D, Abelson MB. Methodologies for the study of ocular 
surface disease. Ocul Surf 2005;3:143-54. 
17. 
Meerovitch K, Torkildsen G, Lonsdale J, et al. Safety and efficacy of MIM-D3 
ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with 
dry eye. Clinical ophthalmology 2013;7:1275-85. 
18. 
Petrov A, Perekhvatova N, Skulachev M, Stein L, Ousler G. SkQ1 Ophthalmic Solution 
for Dry Eye Treatment: Results of a Phase 2 Safety and Efficacy Clinical Study in the 
Environment and During Challenge in the Controlled Adverse Environment Model. Advances in 
therapy 2016;33:96-115. 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 37 of 50 
March 10, 2017   
19. 
Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, 
placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment 
(CAE) model. Clinical ophthalmology 2015;9:877-84. 
20. 
Bond A, Lader M. The use of analogue scales in rating subjective feelings. British 
Journal of Medical Psychology 1974;47:211-8. 
21. 
Benitez-Del-Castillo JM, Moreno-Montanes J, Jimenez-Alfaro I, et al. Safety and 
Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry 
Eye Disease. Invest Ophthalmol Vis Sci 2016;57:6447-54. 
22. 
Feuerstein M, Carter RL, Papciak AS. A prospective analysis of stress and fatigue in 
recurrent low back pain. Pain 1987;31:333-44. 
23. 
Friedman NJ, Butron K, Robledo N, Loudin J, Baba SN, A C. A nonrandomized, open-
label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye 
disease. Clinical ophthalmology 2016;10:795-8. 
24. 
Jeon HS, Hyon JY. The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjogren and 
Sjogren Syndrome Dry Eye Patients Unresponsive to Artificial Tear. Journal of ocular 
pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology 
and Therapeutics 2016;32:463-8. 
25. 
Jeon HS, Youn SW, Jeon HE, Kim JH, Hyon JY. Assessment of Transepidermal Water 
Loss From the Ocular Area in Dry Eye Disease. Invest Ophthalmol Vis Sci 2016;57:4831-6. 
26. 
Lambiase A, Sullivan BD, Schmidt TA, et al. A Two-Week, Randomized, Double-
masked Study to Evaluate Safety and Efficacy of Lubricin (150 mug/mL) Eye Drops Versus 
Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed(R)) in Patients with Moderate Dry Eye 
Disease. Ocul Surf 2017;15:77-87. 
27. 
Merayo-Lloves J, Sanchez-Avila RM, Riestra AC, et al. Safety and Efficacy of 
Autologous Plasma Rich in Growth Factors Eye Drops for the Treatment of Evaporative Dry 
Eye. Ophthalmic research 2016;56:68-73. 
28. 
RC A. Measurement of feelings using visual analogue scales. Proceedings of the Royal 
Society of Medicine 1969;62:989-93. 
29. 
Yokoi N, Kato H, Kinoshita S. The increase of aqueous tear volume by diquafosol 
sodium in dry-eye patients with Sjogren's syndrome: a pilot study. Eye 2016;30:857-64. 
30. 
DEWS. Design and conduct of clinical trials: report of the Clinical Trials Subcommittee 
of the International Dry Eye WorkShop Ocul Surf 2007;5:158. 
31. 
Clinical Outcome Assessments Consult Review - Lifitegrast ophthalmic solution. Center 
for Drug Evaluation and Research, 2016. Accessed 2017, at 
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208073Orig1s000MedR.pdf.) 
32. 
Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for 
treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology 
2014;121:475-83. 
33. 
Tauber J, Karpecki P, Latkany R, et al. Lifitegrast Ophthalmic Solution 5.0% versus 
Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. 
Ophthalmology 2015;122:2423-31. 
34. 
Ousler G, 3rd, Devries DK, Karpecki PM, Ciolino JB. An evaluation of Retaine 
ophthalmic emulsion in the management of tear film stability and ocular surface staining in 
patients diagnosed with dry eye. Clinical ophthalmology 2015;9:235-43. 
35. 
Rodriguez JD, Lane KJ, Ousler GW, 3rd, et al. Diurnal Tracking of Blink and 
Relationship to Signs and Symptoms of Dry Eye. Cornea 2016;35:1104-11. 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 38 of 50 
March 10, 2017   
36. 
Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, 
placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. 
Am J Ophthalmol 2012;153:1050-60 e1. 
37. 
Stonecipher KG, Torkildsen GL, Ousler GW, 3rd, Morris S, Villanueva L, Hollander 
DA. The IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic 
emulsion 0.05% on ocular surface staining and visual performance in patients with dry eye. 
Clinical ophthalmology 2016;10:887-95. 
38. 
Rubin D. Multiple Imputation for Nonresponse Surveys. New York: John Wiley and 
Sons; 1987. 
39. 
Institute S. SAS/STAT® 13.1 User’s Guide. Cary, NC: SAS Institute, Inc.; 2013. 
40. 
Walt JG RM, Stern KL. Evaluating the functional impact of dry eye: the Ocular Surface 
Disease Index [abstract]. Drug In J 1997;31:1436. 
 
15.0 APPENDICES 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 39 of 50 
March 10, 2017   

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 40 of 50 
March 10, 2017   
15.2 
Appendix 2: Examination Procedures, Tests, Equipment, and Techniques 
 
Visual Acuity Procedures 
15.2.1
LogMAR visual acuity should be assessed using an ETDRS chart. The procedure used will be 
consistent with the recommendations provided for using the ETDRS eye chart. Visual acuity 
should be evaluated at the beginning of each visit in the study (i.e., prior to slit lamp 
examination). Participants should use the most recent correction to attain their corrected distance 
visual acuity (CDVA); if they forget their spectacles, this prescription can be placed in a trial 
frame. 
Equipment 
The visual acuity chart to be used is the ETDRS chart. If smaller reproduction (18" by 18", e.g., 
from Prevent Blindness) wall charts are used, the participant viewing distance should be exactly 
10 feet (or as specified by the manufacturer). In ALL cases, for purposes of standardizing the 
testing conditions during the study, all sites should use only ETDRS Series 2000 Chart 1 & 2, 
and the right eye should be tested first. For reflectance (wall) charts, the chart should be placed 
frontally and be well illuminated. 
Measurement Technique 
The chart should be at a comfortable viewing angle. The right eye should be tested first. The 
participant should attempt to read each letter, line-by-line, left to right, beginning with line 1 at 
the top of the chart. The participant should be told that the chart has letters only, no numbers. If 
the participant reads a number, s/he should be reminded that the chart contains no numbers, and 
the examiner should then request a letter in lieu of the number. The participant should be asked 
to read slowly, so as to achieve the best identification of each letter. S/he is not to proceed to the 
next letter until s/he has given a definite response. 
If the participant changes a response (e.g., 'that was a "C" not an "O"') before s/he has read aloud 
the next letter, then the change should be accepted. If the participant changes a response having 
read the next letter, then the change is not accepted. The examiner should never point to the chart 
or to specific letters on the chart during the test. 
A maximum effort should be made to identify each letter on the chart. When the participant says 
s/he cannot read a letter, s/he should be encouraged to guess. If the participant identifies a letter 
as one of two letters, s/he should be asked to choose one letter and, if necessary, to guess. When 
it becomes evident that no further meaningful readings can be made, despite encouragement to 
read or guess, the examiner should stop the test for that eye. However, all letters on the last line 
should be attempted as letter difficulties vary and the last may be the only one read correctly. 
The number of letters missed or read incorrectly should be noted. 
LogMAR Visual Acuity Calculations 
The last line in which a letter is read correctly will be taken as the base logMAR reading. To this 
value will be added the number "N x 0.02" where 'N' represents the total number of letters 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 41 of 50 
March 10, 2017   
missed up to and including the last line read. This total sum represents the logMAR visual acuity 
for that eye. 
Example: Participant correctly reads 4 of 5 letters on the 0.2 line, and 2 of 5 letters on the 0.1 
line. 
Base logMAR 
= 0.1 
N (total number of letters incorrect on line 0.2 as well as 0.1) 
= 4 
N x T (T=0.02) 
= 0.08 
Base logMAR + (N x T) 
= 0.1 + 0.08 
logMAR visual acuity 
= 0.18 
 
Repeat the procedure for the left eye. 
In order to provide standardized and well-controlled assessments of visual acuity during the 
study, all visual acuity assessments at a single site should be consistently done using the same 
lighting conditions and same correction if possible during the entire study. If the same correction 
cannot be used (i.e., a participant broke his/her glasses), the reason for the change in correction 
should be documented. 
Note: A clinically significant visual acuity decrease (defined as an increase of 0.22 or greater in 
logMAR score) from the Screening Visit (Visit 1) should be evaluated by the Investigator as a 
potential AE. 
 
Slit Lamp Biomicroscopy 
15.2.2
Slit lamp biomicroscopy will be performed during the study. Observations will be graded as 
Normal or Abnormal. Abnormal findings, which are clinically significant, will be described. The 
following will be examined at each visit: 
• 
Cornea  
• 
Conjunctiva  
• 
Anterior Chamber 
• 
Lid 
 
  

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 42 of 50 
March 10, 2017   
 Corneal Fluorescein Staining  
15.2.2.1
The examiner should instill 5 µL of 2% preservative-free sodium fluorescein solution into the 
inferior conjunctival cul-de-sac of each eye. Alternatively, corneal staining can be assessed using 
1.0 mg sodium fluorescein strips. After moistening the tip of the strip with sterile buffered saline, 
the excess is shaken into a waste bin with a sharp flick. The lower lid is then pulled down and the 
flat end of the tip should be gently applied to the inferior tarsal conjunctiva with the intent of not 
inducing reflex tearing and instilling a very small volume of dye.  
The participant will be instructed to blink naturally several times without forced closure of the 
eyelid to distribute the fluorescein. In order to achieve maximum fluorescence, the examiner 
should wait at least two minutes after instillation before evaluating corneal fluorescein staining. 
A Wratten #12 yellow filter will be used to enhance the ability to grade fluorescein staining. The 
staining will be graded with the NEI Scale. The upper eyelid is lifted slightly to grade the entire 
corneal surface. 
NEI/Industry Workshop Scale 
Score each of five areas on the cornea of each eye. 
 
Diagram of the division of the corneal surface for measuring fluorescein uptake. A 
standardized grading system of 0-3 is used for each of the five areas on each cornea. Grade 0 
will be specified when no staining is present. The maximum score is 15. 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 43 of 50 
March 10, 2017   
 
Intranasal Examination 
15.2.3
The intranasal examination can be completed without topical anesthesia using nasal endoscopy 
or a nasal speculum. If using endoscopy, the endoscope is gently inserted into each of the nares 
and the nasal cavity is carefully inspected. If using a nasal speculum, the speculum is gently 
inserted into each of the nares. A light should be utilized to enhance visualization. The speculum 
is opened to expand the nares and the nasal cavity is carefully inspected. With the intranasal 
examination, still images or video may be captured.    
The nasal cavity is inspected for vascularized polyp, severely deviated septum, severe nasal 
airway obstruction or evidence of prior surgery/cautery. Any other gross abnormalities or 
irregularities should be documented accordingly.   
 
Basal Schirmer Test with Topical Anesthesia 
15.2.4
The Schirmer test with topical anesthesia will be used to assess tear production using the 
following steps:   
1. One drop of topical anesthetic such as 0.5% proparacaine hydrochloride or equivalent should 
be instilled in each eye of the participant. 
2. The participant will be instructed to keep the eyes gently closed for one minute.   
3. After opening the eyes and allowing the eyes to recover for approximately one additional 
minute, excess moisture in the inferior fornix is gently removed with a spear. 
4. Schirmer strips (35 mm x 5 mm size filter paper strip) will be placed in each eye at the 
junction of the middle and lateral thirds of the lower eye lid.  
5. Under ambient light, the participant will be instructed to look forward and to blink normally 
during the course of the test. The test should be performed in a room with no direct air on the 
participant’s face. 
6. The Schirmer strips should remain in place until five minutes have elapsed or both strips 
have reached maximum score. 
7. After five minutes, strips will be removed from both eyes and the amount of wetting will be 
recorded. The strips should be taped to the CRF.   
 
Schirmer test using cotton swab nasal stimulation   
At the Screening Visit, the Schirmer test should be performed using cotton swab nasal 
stimulation. New anesthetic drops should be instilled following the same procedure specified in 
steps #1 to #3 in the Basal Schirmer Test section. 
   
1. With new strips in place, the examiner should insert cotton swabs in the participant’s two 
nostrils simultaneously and gently probe both nasal middle turbinates for approximately 30 
seconds. After this, the examiner can simply hold the swabs in place, applying gentle 
pressure, and repeat probing intermittently as necessary.   

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 44 of 50 
March 10, 2017   
2. Alternatively, the participant can be instructed to hold the cotton swabs and gently probe 
both nasal turbinates simultaneously, resting intermittently before probing again. The 
examiner should continuously coach the participant on how to perform this test properly.  
3. The Schirmer strips should remain in place until five minutes have elapsed or both strips 
have reached maximum score. 
   
Both Schirmer scores will be recorded and it should be verified that the inclusion criteria have 
been met. 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 3  Target area of cotton swab nasal stimulation  
 
 
Schirmer test during device application   
At Visit 3, the Schirmer test should be performed using the device. New anesthetic drops should 
be instilled following the same procedure specified in the Basal Schirmer Test section. 
   
1. With new strips in place, the examiner should instruct the participant to fully insert the 
device in the nasal cavity and use the device for approximately 3 minutes. As needed, the 
examiner should continuously coach the participant on how to use the device properly.  
2. The Schirmer strips should remain in place until five minutes have elapsed or both strips 
have reached maximum score. 
Middle turbinate 
located intranasally 
approximately 1 to 
2 inches inside nose 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 45 of 50 
March 10, 2017   
 
Dry Eye Questionnaires 
15.2.5
 Ocular Surface Disease Index© (OSDI©) 
15.2.5.1
To minimize bias, participants will be asked to complete the OSDI questionnaire 
independently and in private after instructions have been provided by site personnel. 
The OSDI is a 12-item questionnaire generated by the Outcomes Research Group at 
Allergan (Irvine, CA),40 which asks participants to describe the nature and frequency of 
their irritation symptoms. The participant will answer the 12 questions by circling the 
number that best represents each answer: 4 (all of the time), 3 (most of the time), 2 (half of 
the time), 1 (some of the time), or 0 (none of the time). The final score for the questionnaire 
is calculated as follows: 
Add subtotals from Sections I, II, and III =  A 
Determine total number of questions answered from Sections I, II, and III (do not include 
N/A) = B 
Final OSDI score = A x 25 divided by B   
 
    An example of the questionnaire is as follows: 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 46 of 50 
March 10, 2017   
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 47 of 50 
March 10, 2017   
 
 
 

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 48 of 50 
March 10, 2017   
 Eye Dryness Score (EDS) Visual Analog Scale (VAS) 
15.2.5.2
Participants will be asked the following question regarding eye dryness as specified in the 
protocol. On the CAE visit days, EDS will be collected upon entering the CAE and every 5 
minutes during CAE exposure. The participants will be asked to rate their current eye dryness 
(both eyes simultaneously) by placing a vertical mark on the horizontal line to indicate the level 
of eye dryness; 0 corresponds to “no discomfort” and 100 corresponds to “maximal discomfort.” 
The assessment line length of the scale will be 100 mm and will be similar to the following 
depiction: 
 
Please rate your current eye dryness by drawing a vertical line on the line below: 
                               
 
 
 
                       
 
CalibraTM Ocular Discomfort Scale  
15.2.5.1
 
   
 
 
 
 
 
 
 
No 
Discomfort 
Maximal 
Discomfort 

Clinical Trial Protocol: OCUN-029
Sponsor: Allergan, Inc.
15.3
Appendix 3: Sponsor and
Approvals
Protocol Title:
Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry Eye
Symptom Relief Assessed During Exposure to a Controlled Adverse
Environment (CAE) Following a 45 Day Period with Application of
TrueTearTM
Protocol Number:
OCUN-029
Signed:
Signed:
Date:
Date:_
Date:
Version 1.0
March 10, 2017
Confidential
Page 49 of 50
This clinical study protocol was subject to critical review and has been approved by the sponsor. The
following personnel contributed to writing and/or approving this protocol.
Date:
Date:
Date:

Clinical Trial Protocol: OCIJN-029
Sponsor: Allergan, Inc.
15.3
Appendix 3: Sponsor and
Approvals
Protocol Title:
Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry Eye
Symptom Relief Assessed During Exposure to a Controlled Adverse
Environment (CAE®) Following a 45 Day Period with Application of
TrueTearTM
Protocol Number:
OCUN-029
This clinical study protocol was subject to critical review and has been approved by the sponsor. The
following personnel contributed to writing and/or approving this protocol.
Signed:_______________________________________________
Date:__________________________
Signed:_______________________________________________
Date:__________________________
Signed:_______________________________________________
Date:__________________________
Signed:_______________________________________________
Date:__________________________
Signed:__________________________________________________
Date:___________________________
Signed:_______________________________________________
Date:__________________________
Signed:_______________________________________________
Date:__________________________
Date:___________________________
Version 1.0
Confidential
Page
4
9 of 50
March 10, 2017

Clinical Trial Protocol: OCUN-029 
Sponsor: Allergan, Inc. 
Version 1.0 
Confidential  
Page 50 of 50 
March 10, 2017   
15.4 
Appendix 4: Investigator’s Signature 
Protocol Title: 
Prospective, Single-Arm Clinical Trial to Evaluate Acute Dry Eye 
Symptom Relief Assessed During Exposure to a Controlled Adverse 
Environment (CAE®) Following a 45 Day Period with Application of 
TrueTear™ 
Protocol Number: 
OCUN-029 
 
 
I agree to implement and conduct the study diligently and in strict compliance with the protocol, 
good clinical practices and all applicable laws and regulations. I agree to maintain all 
information supplied by 
and the sponsor in confidence and, when this information is 
submitted to an Institutional Review Board (IRB) or another group, it will be submitted with a 
designation that the material is confidential. 
I have read this protocol in its entirety, including the above statement, and I agree to all aspects. 
Signed: 
 
 
Date:  
 
 
Name:  
 
 
 
Title:  
 
 
 
Site:  
 
 
 
Address:  
 
 
 
Phone Number: